Natera, Inc. (NTRA)

Theseus Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-189.76	-190.43	-434.8	-547.8	-471.72	-229.74
Depreciation & Amortization	29.64	27.47	21.7	16.5	10.15	7.61
Other Amortization	4.16	4.49	3.69	1.46	2.33	1.15
Asset Writedown & Restructuring Costs	-	-	2.68	9.29	35.6	-
Loss (Gain) From Sale of Investments	-0.15	-0.62	1.09	5.74	7.77	5.66
Stock-Based Compensation	287.81	274.43	191.81	152.38	115.22	50.17
Provision & Write-off of Bad Debts	-	-	-	-	-	1.35
Other Operating Activities	15.14	18.18	14.84	14.07	11.01	20.42
Change in Accounts Receivable	-29.49	-35.88	-33.9	-122.31	-43.51	-25.83
Change in Inventory	-7.34	-3.99	-5.35	-8.5	-6.88	-7.47
Change in Accounts Payable	4.86	13.21	-15.46	5.46	19.22	-0.12
Change in Unearned Revenue	0.73	0.85	4.96	2.06	-44.21	-6.9
Change in Other Net Operating Assets	37.51	27.94	1.8	40.14	29.77	1.19
Operating Cash Flow	153.12	135.66	-246.96	-431.5	-335.24	-182.51
Capital Expenditures	-67.92	-66.42	-39.2	-47.7	-49.59	-19.6
Sale (Purchase) of Intangibles	-	-10.5	-	-	-	-
Investment in Securities	50.48	214.54	207.7	378.04	-155.61	-311.86
Investing Cash Flow	-17.45	137.62	168.5	330.34	-205.19	-331.46
Short-Term Debt Issued	-	-	-	30	-	-
Long-Term Debt Issued	-	-	-	-	-	278.32
Total Debt Issued	-	-	-	30	-	278.32
Long-Term Debt Repaid	-	-	-	-	-	-78.76
Total Debt Repaid	-	-	-	-	-	-78.76
Net Debt Issued (Repaid)	-	-	-	30	-	199.56
Issuance of Common Stock	24.36	30.29	254.46	452.64	576.19	301.29
Other Financing Activities	-0.08	-0.08	-	-	-	-
Financing Cash Flow	24.28	30.2	254.46	482.64	576.19	500.85
Net Cash Flow	159.95	303.49	176	381.48	35.76	-13.13
Free Cash Flow	85.19	69.24	-286.15	-479.2	-384.82	-202.12
Free Cash Flow Margin	4.65%	4.08%	-26.43%	-58.42%	-61.52%	-51.69%
Free Cash Flow Per Share	0.67	0.56	-2.49	-4.87	-4.25	-2.50
Cash Interest Paid	7.72	7.9	11.35	8.06	7.08	3.3
Cash Income Tax Paid	1.31	1.31	0.3	0.55	0.28	0.07
Levered Free Cash Flow	120.93	95.45	-181.41	-295.94	-251.3	-130.8
Unlevered Free Cash Flow	125.62	101.14	-174.8	-291.37	-247.34	-121.52
Change in Net Working Capital	-13.26	-10.29	73.41	75.21	32.01	25.53

Updated May 8, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q